James Porter, Nuvalent CEO

Share on LinkedInShare on Twitter

June 9, 2026 02:39 AM EDTUpdated 07:51 AM

Deals

Pharma

GSK to ac­quire Nu­va­lent and its two can­cer drugs un­der FDA re­view for $10.6B

Kyle LaHucik

Biotech Correspondent

GSK is mak­ing one of the largest biotech ac­qui­si­tions in its his­to­ry to gain ac­cess to two ex­per­i­men­tal lung can­cer med­i­cines that are due for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

Think we're worth reading - tell Google.

Confirm Endpoints as a trusted biopharma news source

Confirm on Google

TRENDING NOW

Who pays the best (and worst) in bio­phar­ma? A look at typ­i­cal em­ploy­ee salaries

A fa­ther built a gene ther­a­py for his daugh­ter. He says an FDA re­quest is the bot­tle­neck

Lil­ly of­fers up to $1B for Alzheimer's drug; Bial cuts failed Parkin­son's drug

WuXi AppTec added to Pen­tagon's list of com­pa­nies linked to Chi­nese mil­i­tary

Eli Lil­ly's claims da­ta dead­line may kick off new 340B fight

sponsored

De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy

Read Original at Endpoints News →